Stockreport

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart, Inc.  (VXRT) 
Last vaxart, inc. earnings: 3/19 04:01 pm Check Earnings Report
PDF - Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compare [Read more]